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Abstract
We conducted a prosp ective study of60 patient s in a terti ary care ref erral center to ascertain the status ofcell-me diate d immunity as determ ined by delayed hyp ersensiti vity reactions in patient s with nasopharyngeal carcino ma (N PC) or allergic rhinitis. Delayed hyp ersensiti vity as detected by Mantoux testin g is gene rally accepted as a refl ection of the level of ce ll-mediate d immunoacti vitv-i-the less hyp ersensiti vity rea cti on that occ urs, the lower the level of inununoacti vity is, and vice versa. Ou r study population was made up ofthree gro ups : 20 newly dia gn osed patients with NPC (pretreatme nt) , 20age-and sex-matc hed patients with all ergic rhiniti s, and 20 matched contro ls withou t eithe r disease. A negative Mantoux test (0-to 5-mm induration) was seen in 13 patients with NPC (65.0%), in 17 patient s with all ergic rhinitis (85.0%), and in 16 contro ls (80.0 %) ; none of these differen ces was statistically significant. However; it is interesting that while the NPC gro up had the lowest percentage ofnega tive Mantoux resul ts ove rall, it had the high est percentage ofpatients who had no rea ction at all (i.e., 0-lIl1n induration); a co mp lete abse nce of any reaction was see n in 7 of the 13 Mantoux-negati ve NPC pati ents (53.8 %), compa red with 2 of the 17 Mantoux-n egative allergic rhin itis patients ( 11.8%) and 3 of the 16 Mantoux-negat ive cont rols (18.8% ). An absen ce of a reaction generally indi cates a very limited degree of cell-mediated inununoa cti vity: Theref ore, we conelude that patient s with NPC appear to ha ve sig nificantly less ce llmediated immunity than do patient s with all ergic rhinitis and norm al controls; no statistically sig nificant difference was noted between the latt er two gro ups .
Introduction
Nasopharyngeal ca rcino ma (NPC) is a co mmo n malignan cy among adults see n at the Uni versity Malaya Medical Cent er in Kuala Lumpur. It carries a poor pro gn osis if it is not detected ea rly.
Th e role of immunolo gy in the treatm en t of onco logic di sea se is we ll established. Cytotoxic T cell s and natural killer T ce lls are part of the highl y effic ient defense mechan ism that keep s ec topic malignant cells in check. However, the fac tors tha t reg ulate this mechani sm are still largel y unclear.
Som e recent studies have sugges ted the possibil ity that patient s with NPC ex pe rience a redu cti on in ce ll-mediated immunoacti vit y.' Moreover, NPC appears to have an inverse relati on ship with allergic rhin itis, and possibl e immunol ogic associations have been impli ed. Th e possibility of cross -reac tivity be twee n a type I hypersen sitivity reaction (e.g., nasal alle rgy) and a type 4 hypersen sit ivity reac tion (esse ntially cell-medi ated immunoacti vity) has been postul ated ." If thi s hypoth esis is true , the degree of cell-med iated immunity sho uld be low er in patients with NP C than in patient s with allergic rh init is. T-Iymphocyte dysregul ation has also been show n to pla ya majo r ro le in airway allergy.' Th e go al of thi s study was to asce rta in the ce ll-mediated immune status of patients with NPC and to compare it with the status of patient s with allergic rhiniti s and norm al co ntro ls.
Patients and methods
Cand idates for thi s pro specti ve study we re recruited from the ENT clinic at our tert iary care referral center during 2003. Becau se a delayed hypersensiti vity reacti on to a previou sly sens itize d antige n occ urs, pati ent s who had not been previou sly vac cinated with bacill e Calmett e-Gu erin (BCG) we re not e ligi ble for this study. A negati ve BCG status was determined by a thorou gh history and by the abse nce of a BCG sca ro n the upper forearm. Also excl uded we re patient s who we re suspec ted of being immunocomprom ised and pati ent s who had a histo ry of pulmon ary • to test for ex pos ure to spec ific diseases, such as tuberculos is (Ma ntoux test)
Discussion
NPC is one of the most co mmo n mali gnant tumors of the head and neck . It has a tend en cy to sprea d rapidly to the regional nec k nodes and to metastasize to the bones, liver, and lun gs. Its etiology is multifactorial ; ge netic fac tors , Epstein-B arr virus (EBV) , and env iro nmental fac tors that activate EBV have all been rep or ted to co ntribute. Ev idence is increasing that EBV plays the primary role in the development of NPC. 4 A delayed hypersensitivity test is an immune function assessme nt tha t measures the presen ce of activated T ce lls that recog nize a cer tain substa nce . After an initial ex pos ure to a foreign substa nce or antigen, the immune sys tem creates antibodies and sens itized T ce lls. Both of these immune sys tem age nts resp ond when the body is re-exposed to the ant igen . Th e anti bodies, which are circ ulating protein s, respond within mi nutes and elicit an immediate hypersensiti vity reaction . T he T cells respond ove r a period of seve ral days, and thus they elicit a delayed hypersensitivity reaction.
The reaction to tuberculin antigens, wh ich is elicited by the Mantou x test, is a classic example of a delay ed hypersensit ivity reac tion. T he tuberculin skin test is able to asse ss the vitality of the T-cell res po nse. The casc ade of events initiated by T ce lls ca n lead to hardenin g (indurat ion) and ery thema at the inject ion site.' An abse nce of reac tion indicates a lack of T-cell responsive ness, which is a characteristic finding in patient s with immune deficiency diseases.' An intact immune sys tem is esse ntial for the development of a positive sk in test; co nverse ly, any imp airmen t of the ce ll-med iated immun e res ponse ge nerally results in a mini mal or absent react ion and thus a negative test."
A delayed hypersensitivity test is per formed for one of three reasons: significa nt; the difference between the allergic rhinitis patient s and the co ntro ls was not sig nifica nt.
Mantoux result (induration)

Results
A negati ve Mant oux test was see n in 13 patient s with NPC (65 .0%), in 17 patient s with allergic rhinitis (85.0%) , and in 16 co ntro ls (80 .0%) (table). None of these diffe rences was statistically significa nt.
Altho ugh the NPC gro up had the lowest overall perce ntage of negative Ma nto ux result s, it had the highest percent age of patient s who had no reaction at all (i.e ., O-mm ind uratio n). A co mplete abse nce of any reaction was see n in 7 of the 13 Mantou x-negati ve NPC patient s (53 .8%), co mpared with 2 of the 17 Mantou x-negative allergic rhinitis patie nts ( 11.8%) and 3 of the 16 Mant ou x-negative co ntro ls ( 18.8%) . Th e differences between the NPC gro up and bo th of the other two gro ups were statistica lly • One gro up was made up of patient s wit h newly d iagnosed and as-yet -untreated NPC. Th e presence of the cancer was co nfirmed by analysis ofhistologic speci mens obtained fro m the postnasal space or the fossa of Rosenm Uller.
• T he second gro up was made up of patients who had a cl inica l diag nosis of allergic rhiniti s.
• Th e co ntro l gro up was made up of subjects who had no history of allergic rhinitis or any malignan cy.
Afte r prov iding infor med co nse nt, all patient s underwent a Mant ou x test. Ma ntoux testing elicits a delayed hypersensitivity reaction to a previously sensitized antige n (a T-lym phocyte function), and it is ge nera lly acce pted as a valid in vivo indicator of a patie nt' s level of ce ll-me diated immunity. A co mplete abse nce of a response ge nerally indicates an imp airment of T-ce il functio n, whic h re flects a low degree of ce ll-med iated imrnunoactivity, Ma ntoux testing was performed with tubercul in purified pro tein derivative (PPO) RT 23 SSI (Statens Se rum Institut; Copenhage n). Eac h via l co ntained I ml of tuberc ulin PPO at a strength of 2 TUfO.1 ml .
T he res ults ofall Man tou x tests were read ap prox imately 72 hours after inoc ulatio n (mos t positi ve result s beco me evi de nt in 8 to 72 hours). Indu rat ions were measured transversely to the long ax is of the forear m with a clear, flexible sca le. Results we re categorized as negative (0-to 5-mm induration), positive (6 to 14 mm ), and strongly positive (~15 mm ). tubercul osis or who had bee n in close co ntact wit h such a patien t.
We chose 60 patients-36 men and 24 wo me n-to serve as our study population. Based on their pathology, patients were ass igned to one of three age-and sex-matc hed groups; eac h gro up was made up of 12 men and 8 wome n, aged 32 to 63 years (mea n: 41):
Volume 86, Number 5 • to test for alle rgic se nsitivity to potent ial skin irritants (s kin-prick test)
• to assess the vita lity of the T-cell res po nse as part of an evaluation of the immune system in patient s with an infection, ca ncer . or an immune disord er, and as a scree ning too l for older patien ts, maln ouri shed patient s, and those who are scheduled to undergo organ tran splant ation?
Cell-med iated immun ity is apparen tly an impor tant element of the host defe nses aga inst cancer. A growing body of inform ati on on cell-mediated immunity to EBV is providing a stro ng basis for research o n immunoreactivity in NPC. Ce ll-med iate d immune res po nses to viruses and tum or-associat ed anti gens may have impli cati ons for enha ncing our kno wledge of the etiology, d iag nosis, and treatm ent of NPC in the near fu ture.'
Our finding that patien ts with NP C have a low degree of ce ll-media ted immun ity co nfirms a findin g by Hsu et al, who published the results of their study of 344 patien ts with NPC in I980. x Two years earlie r, Ch an et al reported that newly diag nosed NPC patient s had an imp aired T-ce ll function that was associated wit h poor surv ival."
Th e progn osis for patient s with NPC is ge nera lly poor, largely becau se it is difficult to detect in its ea rly stages. Thi s ca nce r ca n arise seconda ry to the failure of an immunosur veill ance mech an ism in which immunoresponsiveness is ex treme ly depressed. Immunologic status has been examined, and the clinica l eva luatio n of immunotherapy and lym phocyte tra nsfer has been performed by Tsukud a and Sawaki.t'Th ey found that deficiencies ofce llular immunity co uld be recognized through the various immuno log ic parameters and immunotherapy. Th ey suggested that this is indispen sable in this cancer treatm ent.
